Valuation Update With 7 Day Price Move • May 14
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩9,390, the stock trades at a trailing P/E ratio of 20.5x. Average trailing P/E is 40x in the Biotechs industry in South Korea. Total loss to shareholders of 11% over the past year. Buy Or Sell Opportunity • Apr 09
Now 20% overvalued Over the last 90 days, the stock has fallen 6.7% to ₩7,710. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company has become profitable. Buy Or Sell Opportunity • Mar 20
Now 21% overvalued Over the last 90 days, the stock has fallen 11% to ₩7,750. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Meanwhile, the company has become profitable. Buy Or Sell Opportunity • Mar 05
Now 22% overvalued Over the last 90 days, the stock has fallen 7.1% to ₩7,800. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Meanwhile, the company has become profitable. 공시 • Feb 13
J2KBIO Co., Ltd., Annual General Meeting, Mar 27, 2026 J2KBIO Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 50-3, dureungyuri-ro, ochang-eup, cheongwon-gu, chungcheongbuk-do, cheongju South Korea Valuation Update With 7 Day Price Move • Dec 17
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩9,720, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 3.8% over the past year. Reported Earnings • Nov 13
Third quarter 2025 earnings released: EPS: ₩143 (vs ₩45.00 loss in 3Q 2024) Third quarter 2025 results: EPS: ₩143 (up from ₩45.00 loss in 3Q 2024). Revenue: ₩8.56b (up 32% from 3Q 2024). Net income: ₩838.4m (up ₩1.09b from 3Q 2024). Profit margin: 9.8% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. New Risk • Apr 13
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.8% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 25% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩65.2b market cap, or US$46.0m). Reported Earnings • Mar 30
Full year 2024 earnings released: ₩299 loss per share (vs ₩1,001 profit in FY 2023) Full year 2024 results: ₩299 loss per share (down from ₩1,001 profit in FY 2023). Revenue: ₩33.1b (up 16% from FY 2023). Net loss: ₩1.65b (down 134% from profit in FY 2023). New Risk • Feb 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩66.1b market cap, or US$45.9m). 공시 • Feb 15
J2KBIO Co., Ltd., Annual General Meeting, Mar 28, 2025 J2KBIO Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 50-3, dureungyuri-ro, ochang-eup, cheongwon-gu, chungcheongbuk-do, cheongju South Korea New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩55.0b market cap, or US$38.3m). Reported Earnings • Nov 12
Third quarter 2024 earnings released: ₩45.00 loss per share (vs ₩283 profit in 3Q 2023) Third quarter 2024 results: ₩45.00 loss per share (down from ₩283 profit in 3Q 2023). Revenue: ₩6.51b (down 16% from 3Q 2023). Net loss: ₩250.3m (down 118% from profit in 3Q 2023). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 36% growth forecast for the Biotechs industry in South Korea. Buy Or Sell Opportunity • Nov 08
Now 24% overvalued Over the last 90 days, the stock has fallen 28% to ₩13,270. The fair value is estimated to be ₩10,718, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 70% over the last year. Earnings per share has declined by 73%. Valuation Update With 7 Day Price Move • Oct 29
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩13,810, the stock trades at a trailing P/E ratio of 78.2x. Average forward P/E is 23x in the Biotechs industry in South Korea. Buy Or Sell Opportunity • Aug 02
Now 21% undervalued Over the last 90 days, the stock has risen 5.9% to ₩18,900. The fair value is estimated to be ₩23,836, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 73% over the last year. Meanwhile, the company became loss making. New Risk • Jun 27
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩135.5b (US$97.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risk Market cap is less than US$100m (₩135.5b market cap, or US$97.9m). Valuation Update With 7 Day Price Move • May 10
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to ₩22,600, the stock trades at a trailing P/E ratio of 26x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Buy Or Sell Opportunity • May 10
Now 23% overvalued The stock has been flat over the last 90 days, currently trading at ₩22,600. The fair value is estimated to be ₩18,317, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Valuation Update With 7 Day Price Move • Apr 20
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₩16,340, the stock trades at a trailing P/E ratio of 18.8x. Average trailing P/E is 21x in the Biotechs industry in South Korea.